Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Estimated Prevalence of JAK2 V617F Mutations High in General Danish Population

The driver mutation JAK2 V617F and Calreticulin (CALR) mutations constitute major diagnostic criteria of myeloproliferative neoplasms (MPNs), and, while JAK2 V617F has been detected...
WIB_icon

Risk of Severe GVHD Lower With Post-Transplant Cyclophosphamide Than ATG in Mismatched Unrelated Donor...

Antithymocyte globulin (ATG) is considered standard graft-versus-host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) who undergo transplantation with a mismatched unrelated...
WIB_icon

Short, Aggressive Antibiotic Therapy Inhibits Lymphocyte Proliferation in CTCL

According to a study published in Blood, patients with advanced-stage cutaneous T cell lymphoma (CTCL) a short, yet aggressive, antibiotic regimen inhibited disease activity...
WIB_icon

Equal Access to Treatment Erases Difference in Outcomes Between White and African American Patients...

If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...
WIB_icon

Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma

According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...
WIB_icon

Study Finds Urgent Need for Sickle Cell Disease Screening Among African Refugees in Italy

Most refugees who arrive at the Mediterranean coast of Italy and other southern European countries are leaving areas where sickle cell disease (SCD) is...
WIB_icon

Walking Speed Predicts Frailty, Survival, and Other Outcomes in Older Patients With Blood Cancers

Walking speed was a reliable indicator of frailty among older patients with blood cancers, and this frailty measure was a more accurate predictor of...
WIB_icon

Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma

In patients with high-risk, relapsed/refractory classical Hodgkin lymphoma (cHL) who have undergone autologous hematopoietic cell transplantation (AHCT), consolidation therapy with the PD-1 inhibitor pembrolizumab...
WIB_icon

New Study Supports “R2” Regimen in Previously Untreated Follicular Lymphoma

The combination of lenalidomide and rituximab, known as the R2 regimen, improved progression-free survival (PFS), time to next treatment (TTNT), and complete response (CR)...
WIB_icon

Higher Dose, Longer Duration of Eltrombopag Improves Likelihood of Response in Refractory Severe Aplastic...

The thrombopoietin receptor agonist eltrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with refractory severe aplastic anemia...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.